The FDA gave a lift to the diagnostic group, providing Ostex International Inc. and T Cell Sciences Inc. their first product approvals, and adding a second product to SangStat Medical Corp.'s transplantation portfolio.

Ostex International Inc. (OSTX)
OSTX received FDA marketing approval for its Osteomark urine test to measure bone resorption. The non-disease specific assay can measure bone loss resulting from a variety of conditions. The test measures levels of cross-linked N-telopeptides (NTx), which are a direct degradation product of mature bone and are excreted in urine. Results are available